WebDisclosure WebDisclosure
Basculer en Français
10771 Companies
232039 Keywords
160518 Articles
123515 Press releases
Headlines Articles Press releases Ebenbuild GmbH Remove
  1. Home
  2. Companies
  3. Ebenbuild GmbH
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/15/2026 at 11:05, 3 months 12 days ago

    Ebenbuild Validates Lung Digital Twins in Nature Communications Medicine

    Respiratory Medicine Predictive Modeling Clinical Validation Lung Digital Twins Inhaled Drug Development
  • BRIEF

    published on 04/15/2026 at 11:05, 3 months 12 days ago

    Ebenbuild valide les jumeaux numériques pulmonaires dans Nature Communications Medicine

    Modélisation Prédictive Validation Clinique Jumeaux Numériques Pulmonaires Développement De Médicaments Inhalés Pneumologie
  • PRESS RELEASE

    published on 04/15/2026 at 11:00, 3 months 12 days ago

    Ebenbuild publishes validation study in Nature Communications Medicine demonstrating strong predictive performance of lung digital twins

    Ebenbuild publishes validation study in Nature Communications Medicine demonstrating strong predictive performance of lung digital twins. Study validates drug deposition prediction in human lungs
    Lung Digital Twins Ebenbuild Validation Study Predictive Performance Drug Deposition
    Logo of Ebenbuild GmbH
Accesswire
  • Published on 07/27/2026 at 14:00, 12 hours 59 minutes ago

    Silver Storm Announces First Concentrate Shipment from La Parrilla

  • Published on 07/27/2026 at 13:30, 13 hours 29 minutes ago

    International Battery Metals Announces CEO Transition

  • Published on 07/27/2026 at 13:30, 13 hours 29 minutes ago

    Strategic Metals Options Yukon Copper-Gold Projects to GGL Resources Corp.

  • Published on 07/27/2026 at 13:30, 13 hours 29 minutes ago

    Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares; Closing Expected in October 2026

  • Published on 07/27/2026 at 13:30, 13 hours 29 minutes ago

    Reeflex Announces Updated Investor Presentation and Upcoming Investor Conference Participation

View all ACCESSWIRE
EQS Group
  • Published on 07/27/2026 at 23:05, 3 hours 54 minutes ago

    Quantinuum to Report Second Quarter Financial Results on August 11, 2026

  • Published on 07/27/2026 at 22:45, 4 hours 13 minutes ago

    EQS-Adhoc: Hypoport SE: Gross profit growth and significant increase in EBIT in H1/26

  • Published on 07/27/2026 at 21:15, 5 hours 44 minutes ago

    Xryma Plc announces the upcoming launch of XrymaCoin (XREUR), the regulated euro stablecoin designed to work like money

  • Published on 07/27/2026 at 20:50, 6 hours 9 minutes ago

    Pentixapharm Completes Capital Increase – New Shares Placed in Full

  • Published on 07/27/2026 at 20:40, 6 hours 18 minutes ago

    EQS-Adhoc: Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today

View all EQS
Les Echos
  • Published on 07/27/2026 at 18:00, 8 hours 59 minutes ago

    Saint-Gobain accélère en Asie avec deux acquisitions ciblées

  • Published on 07/27/2026 at 18:00, 8 hours 59 minutes ago

    Saint-Gobain accelerates in Asia with two targeted acquisitions

  • Published on 07/27/2026 at 17:45, 9 hours 14 minutes ago

    Weekly share buyback

  • Published on 07/27/2026 at 17:45, 9 hours 14 minutes ago

    Déclaration hebdomadaire de rachat d'actions

  • Published on 07/27/2026 at 17:40, 9 hours 19 minutes ago

    260727 BENETEAU CA S1 2026 FR

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy